Predictors of responses to immune checkpoint blockade in advanced melanoma by Jacquelot, N et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Predictors of responses to immune checkpoint blockade in advanced melanoma
Jacquelot, N; Roberti, M P; Enot, D P; Rusakiewicz, S; Ternès, N; Jegou, S; Woods, D M;
Sodré, A L; Hansen, M; Meirow, Y; Sade-Feldman, M; Burra, A; Kwek, S S; Flament, C;
Messaoudene, M; Duong, C P M; Chen, L; Kwon, B S; Anderson, A C; Kuchroo, V K; Weide,
B; Aubin, F; Borg, C; Dalle, S; Beatrix, O; Ayyoub, M; Balme, B; Tomasic, G; Di Giacomo, A
M; Maio, M; Schadendorf, D; Melero, I; Dréno, B; Khammari, A; Dummer, R; Levesque, M;
Koguchi, Y; Fong, L; Lotem, M; Baniyash, M; Schmidt, H; Svane, I M; Kroemer, G; Marabelle,
A; Michiels, S; Cavalcanti, A; Smyth, M J; Weber, J S; Eggermont, A M; Zitvogel, L
Published in:
Nature Communications
DOI:
10.1038/s41467-017-00608-2
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternès, N., Jegou, S., ... Zitvogel, L. (2017).
Predictors of responses to immune checkpoint blockade in advanced melanoma. Nature Communications, 8,
[592]. https://doi.org/10.1038/s41467-017-00608-2
Download date: 03. Feb. 2020
ARTICLE
Predictors of responses to immune checkpoint
blockade in advanced melanoma
N. Jacquelot et al.#
Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical
armamentarium against metastatic melanoma (MMel). Given the frequency of immune
related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or
PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an
assessment of 779 paired blood and tumor markers in 37 stage III MMel patients,
we analyzed association between blood immune parameters and the functional immune
reactivity of tumor-inﬁltrating cells after ex vivo exposure to ICB. Based on this assay,
we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with
ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and
progression-free survival. Moreover, detectable CD137 on circulating CD8+ T cells was
associated with the disease-free status of resected stage III MMel patients after adjuvant
ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in
prospective trials in MMel.
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The recent development of immune checkpoint blockers(ICBs) has rekindled interest in the ﬁeld of immune cancertherapies1, 2. Cancer vaccines3, adoptive T cell transfer and
CAR T cells4, 5, bispeciﬁc antibodies6, ICBs7, 8 and oncolytic
viruses9 have come of age and many immune agents have recently
entered the oncological armamentarium. However, to date,
immunotherapy has only been shown to provide durable clinical
beneﬁt in a fraction of patients. The recent characterization of
multiple immune resistance mechanisms by which tumors can
evade the immune system has fueled the development of novel
agents that circumvent such limitations, targeting new “immune
checkpoints”. It is likely that the use of combination strategies will
increase the number of cancer patients that might beneﬁt from
immunotherapy10. Nonetheless, a number of critical problems
remain to be solved. First, the scientiﬁc rationale supporting
the use of combinatorial regimens needs to be deﬁned.
Second, it must be determined whether the future success of
immuno-oncology (I-O) will rely on patient stratiﬁcation in large
cohorts or will be personalized to each patient. Depending on
tumor characteristics (e.g., PD-L1 or PD-1 expression on
tumor cells for anti-PD-1 mAb11–13, HMGB1 and LC3B for
immunogenic chemotherapy14, or tumor microenvironment
hallmarks such as IDO expression15, macrophage density16,
tumor-inﬁltrating lymphocytes [TIL], or Th1 ﬁngerprints17), one
might envisage more speciﬁc and individualized I-O clinical
management strategies. Third, predictive immune proﬁles or
biomarkers will need to be validated prospectively to guide I-O
utilization in a personalized or stratiﬁed manner.
We attempted to address some of these questions in patients
with stage III melanoma18, given that (i) optimizing adjuvant I-O
therapies for metastatic melanoma (MMel) remains an unmet
clinical need, (ii) MMel represents a clinical niche for the
development of many mAbs and ICBs, (iii) in these patients,
metastatic lymph nodes (mLN) are surgically resected,
enabling immunological investigations, and (iv) immune
prognostic parameters have been recently described in stage
III/IV MMel19, 20. The tumor microenvironment has a high level
of complexity in its regulation. Each checkpoint/co-stimulatory
pathway displays an independent mechanism of action. This
will require a comprehensive analysis of their mode of action in
the tumor microenvironment in any given patient to design
appropriate combinatorial approaches and to discover speciﬁc
biomarkers of response. Herein, we use a systems biology-based
approach aimed at deﬁning relevant immunometrics for
prediction of an in situ response to cytokines and monoclonal
antibodies (mAb) (i.e., agonists and blockers of immune
checkpoints) in patients with resected stage III melanoma. In this
study, we ﬁrst describe a suitable “ex vivo metastatic lymph node
(mLN) assay”, and through this assay, we demonstrate novel
markers for the efﬁcacy of ICB. We then observed,
through multivariate analyses performed on eight pooled cohorts
including 190 samples of unresectable stage III and IV melanoma,
that PD-L1 expression on peripheral blood CD4+ and CD8+
T cells is prognostic on overall survival (OS) and on progression-
free survival (PFS), while in resected stage III melanoma,
detectable CD137+CD8+ peripheral blood T cells predicted a lack
of relapse with ipilimumab + nivolumab combination therapy.
We conclude that i) the “ex vivo metastatic lymph node (mLN)
assay” represents a suitable method to identify biomarkers for
ICB and ii) PD-L1 expression on blood CD8+ T cells can be a
useful marker of resistance to CTLA-4 blockade that needs to be
prospectively validated.
Results
Functional immunological assays on ex vivo dissociated mLN.
The study population of the ex vivo metastatic lymph node
(mLN) assay consisted of stage III MMel patients undergoing
surgery for lymph node metastases, as previously described19. Of
these patients, one third presented with more than three involved
LN at surgery, 55% had a mutated BRAF oncogene, >30% had
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Fig. 1 Typiﬁcation of responses for each axis of stimulation. Summary of Supplementary Figs. 3−5 showing mLN responding to each axis (CTLA-4, PD-1,
Tim-3, or combinations, together or with cytokines) by speciﬁc immunometrics shared by at least 20% of patients. M&M detail the experimental settings.
Brieﬂy, functional assays used ﬂow cytometry determination of early (18–24 h post-stimulation) intracellular cytokine release in T and NK cells, late (day
4–5 post-stimulation) proliferation assays, chemokine and cytokine secretions in the supernatants at 18–24 h. A biological response to a given axis was
scored “positive” when two independent readouts, reaching a >1.5-fold increase or decrease over two background levels (that of the medium and the
isotype control Ab) were achieved
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thyroid dysfunction, and >50% were scheduled to undergo
adjuvant therapy. Of primary lesions, 52% were ulcerated.
After mechanical and enzymatic digestion of mLN19, CD45–
cells represented 4–98± 4.8% of all cells. The composition of
tumor-inﬁltrating immune cells was analyzed by ﬂow cytometry
with gating on live cells in 39 tumor specimens that were paired
with autologous peripheral blood cells. Analyses were based on a
comprehensive immunophenotyping of 252 parameters (124
in blood and 128 in tumor) per patient, featuring cell type,
activation status, naive or memory phenotype, and activating
or inhibitory receptors or ligands. We previously found
that peripheral blood cell markers were as relevant as TIL
immunotypes for OS and PFS of stage III/IV MMel and para-
meters associated with lymphocyte exhaustion/suppression were
associated with greater clinical signiﬁcance compared to those
related to activation or lineage19. The next step consisted of
analyzing the dynamics of these parameters after incubation with
mAbs± cytokines in 37 patients. Comprehensive assessment
of the reactivity of various subsets of inﬁltrating tumor cells
targeting four functional axes, cytokines and their combinations
is described (Supplementary Fig. 1 and Supplementary Table 1).
A biological response to a given axis was scored “positive”
when two independent readouts, reaching a >1.5-fold increase
or decrease over two background levels (that of the medium and
the isotype control Ab) were achieved. We prioritized
fold changes over p-values, to reduce false positive candidates
(with minimal fold changes, yet very low p-values due to small
variances). Admittedly, this is an arbitrary choice to select robust
effects in the test cohorts but undertook in vivo validation
henceforth.
The “inter-rater agreement” was next evaluated. The
inter-individual variability for specimen manipulation, ELISA
and ﬂow cytometry analyses was minimal, as demonstrated by
two specimens handled by the two ﬁrst authors independently
(Supplementary Fig. 2). Overall, the correlation between the
original readings (from ELISA or FACS experiments) was found
to be highly satisfactory (Spearman correlation= 0.947/0.857
for patient Pt12/Pt24, number of measurements= 259). When
compensating/normalizing to the IgG or control medium, and
thus making the data comparable and directly exploitable for
the immunometrics scoring, the intraclass correlation remained
highly signiﬁcant (ICC= 0.84 (Pt12) and 0.87 (Pt24)) across all
axes considered in the study. Charts depicting the overall
relative levels of reactivity in “ex vivo responders” vs.
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Fig. 2 Global representation of the patterns of responses to individual or combined stimulations for 37 MMel. a, b Venn diagram representing each
stimulating axis alone a or in combination b per circle, patients being identiﬁed by letters and numbers. c Frequencies of patient lesions that failed to
respond to a given axis (ﬁrst bar, in red) but could exhibit signiﬁcant responses to alternative axis of stimulation. (second and third bar in green and blue). For
instance (very left bars), in the non-responding lesions (NR) to anti-CTLA-4 Ab, we annotated the percentages that could respond (or not) to anti-CTLA-4
+ anti-PD-1 Ab co-blockade (in green), among which some of them could respond (or not) to anti-PD-1 Ab alone (in blue). The detailed patterns of
responses feature in Supplementary Table 1. In gray boxes: Not Done
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“ex vivo non-responders” for each biological readout and culture
condition are presented in Supplementary Figs. 3−5. As a positive
control, ex vivo IL-2 stimulation of mLN frequently induced T
and NK cell proliferation, as well as cytokine release mostly by
NK cells (Fig. 1, Supplementary Fig. 3). Additionally, ex vivo
stimulation with rIFNα2a led to high CXCL10 release (Fig. 1 and
Supplementary Fig. 3). mLN responding ex vivo to PD-1
blockade exhibited T-cell proliferation and chemokine release
(CCL2, CCL4, and CXCL10) in 20–33% of cases (Fig. 1 and
Supplementary Fig. 4). mLN responding ex vivo to CTLA-4
blockade demonstrated polyfunctional T-cell activation (in 28
and 42% of responders for CD8+ and CD4+ T cells, respectively)
and chemokine release (CCL4, CCL5, and CXCL9 in 30–40% of
responders) (Fig. 1 and Supplementary Fig. 4). mLN responding
ex vivo to CTLA-4/PD-1 co-blockade typically showed NK cell
proliferation (in 46% of responders) and CXCL10 release (in 50%
cases) (Fig. 1, Supplementary Fig. 5). Anti-Tim-3 mAb led to NK
and CD4+ T-cell proliferation, inﬂammatory cytokines and
CCL4/CCL5 production in 2–3 out of 6 responding lesions
(Fig. 1, Supplementary Fig. 5). mLN responding ex vivo to
CD137/CD137L stimulation exhibited CD8+ T-cell proliferation
accompanied by IL-1β, IL-6, and TNFα release in 30−37% of
responding lesions (Fig. 1, Supplementary Fig. 5).
The Venn diagrams detailing the patterns of immune
reactivities are depicted in Fig. 2. The proportions of mLN
“ex vivo responding” to at least one I-O axis were ~ 30–50
and 50–60% for mAb combinations (Supplementary Table 1,
Fig. 2a, b). The proportion of mLN “ex vivo responding” to both
anti-CTLA-4 and anti-PD-1 mAb separately was 11/37 (30%),
among which 45% failed to respond to concomitant blockade
(Supplementary Table 1). Sixty percent (17/28) of mLN were
“ex vivo responders” to agonistic anti-CD137/anti-CD137L mAb
among which 35% (6/17) failed to respond to any of the classical
ICBs (anti-CTLA-4 or anti-PD-1 mAbs) (Supplementary Table 1).
The likelihood of “ex vivo response” to any alternate ICB or mAb
combination in cases failing to respond to any one monotherapy
or combination therapy is depicted in Fig. 2c. Altogether, our
ex vivo mLN assay is a feasible test potentially allowing a
diagnosis of prediction of ex vivo response to 11 conditions of
stimulation.
Predictive biomarkers of resistance to CTLA-4 blockade. We
next addressed whether predictive biomarkers of a functional
response obtained in the ex vivo mLN assay could be inferred
from the 779 blood/tumor parameters. Multivariate analyses
by means of PCA on all available information are routinely
performed to assess variance structure in the data and in
particular for quality control purposes to identify potential
outlying samples and/or features. This analysis did not reveal
obvious clustering of the samples and their distribution on the
ﬁrst few components could not be signiﬁcantly associated to any
clinical parameters. Very few statistically signiﬁcant immune
parameters predicting responses to CTLA-4 blockade could be
found (Fig. 3a, b and Supplementary Fig. 6a, b).
The strongest predictive biomarkers of ex vivo resistance
to CTLA-4 blockade were elevated PD-L1 expression on
circulating CD4+ T cells (Fig. 3a, c, AUC= 0.79, p< 0.01,
(Wilcoxon rank-sum test)) and CD8+ T cells (Fig. 3a, d, AUC
= 0.76, p< 0.03 [Wilcoxon rank-sum test] without adjustment for
multiple comparisons) but not on the tumor-inﬁltrating
lymphocytes in lymph node melanoma metastases (Fig. 3b and
Supplementary Fig. 6c, d). Hence, pending further evaluation
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Fig. 3 PD-L1 expression on T cells predicts reactivity to ipilimumab in the “ex vivo mLN assay”. a, b Display of the Wilcoxon rank-sum test p-values vs. the
log transformed ratio between responders (R) and non-responders (NR) to anti-CTLA-4 Ab in blood a or tumor b samples. Each dot represents one marker;
selected biomarkers are shown in red while biomarkers with very low level of expression are shown in gray. c, d Expression levels of PD-L1 on blood CD4+ c
and CD8+ d T cells in patient lesions responding (R) or not (NR) to the ex vivo mLN assay using a stimulation with anti-CTLA-4 mAb. Each dot represents
one patient. The absolute numbers of patients are indicated in parentheses in both groups. Graphs were analyzed by Wilcoxon rank-sum test. Box and
whiskers plots are represented from the corresponding distribution c, d
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(see below) this potential biomarker may be relevant to
circulating T lymphocytes but not to the tumor immune inﬁltrate.
Other potential biomarkers such as CD95 expression (best
signiﬁcance in blood for CD8+ T cells, p= 0.08, [Wilcoxon
rank-sum test] and in tumors for CD4+ T cells, p< 0.01
[Wilcoxon rank-sum test], Supplementary Fig. 6e−h) were also
selected in the model. Of note, CD95 membrane expression on
CD4+ T cells was dominant in Treg and chronically activated
CD4+ T cells as well as terminally differentiated effector CD8+
T cells (but not naive T cells, Supplementary Fig. 7a, b),
and highly correlated with HLA-DR and PD-1 expressions
(Supplementary Fig. 7c, d). Additionally, although retained in the
statistical analyses, some biomarkers were not considered further
due to their weak detectability (<2% expression) and low
robustness of their ﬂow cytometric analyses.
Although the aforementioned correlations between immune
parameters and in vitro/ex vivo response patterns were weak
(in the sense that they were only borderline signiﬁcant), we
hypothesized that PD-L1 and/or CD95 on circulating CD4+ and
CD8+ T cells might predict resistance to CTLA-4 blockade in
MMel. We therefore decided to investigate these parameters in
another patient cohort to correlate these immune parameters
with in vivo responses to CTLA-4 blockade in MMel.
Ipilimumab not only improves overall survival in stage IV
MMel but also impacts overall survival, recurrence-free survival
and distant metastasis-free survival in resected high-risk stage III
melanoma21, 22. Based on the results of the “ex vivo mLN assay”,
we retrospectively evaluated the previously selected biomarkers
PD-L1 and CD95 on clinical response and survival outcomes
(overall survival and progression-free survival). Data were
available for 190 unresectable stage III and IV MMel patients
treated with 3 mg/kg (in 90% cases) of ipilimumab in eight
cohorts from different centers. The median follow-up is
30 months (95% Conﬁdence Interval (CI): 26–34). Patients’
characteristics are presented in Supplementary Table 2. PD-L1
and CD95 were evaluated retrospectively at diagnosis in whole
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blood or peripheral blood mononuclear cells (PBMCs) (after
density gradient separation of cells) by ﬂow cytometry gating on
CD4+ and/or CD8+ T cells using a standardized methodology
validated for all centers (either performed by our laboratory, after
thawing of cryopreserved cells or by the investigators themselves
using our antibodies and procedures). CD95 expression levels
were higher in MMel compared with healthy volunteers (HV) in
blood T cells (Fig. 4a). Although variable according to centers and
individuals, PD-L1 expression levels were highly detectable in
circulating CD4+ (Fig. 4b) and CD8+ (Fig. 4c) T cells in stage III/
IV MMel patients, while remaining below the threshold of
conﬁdence in HV (Fig. 4b, c). Additionally, no signiﬁcant
expression was observed between PD-L1 expression on CD8+
T cells and either the LDH status (p= 0.71, [Student’s t-test]
comparing center-speciﬁc high vs. low LDH levels) or the
metastases localization (Fig. 4d). On the other hand, PD-L1
expression on CD8+ and CD4+ T cells are highly correlated (rho
= 0.83, Fig. 4e) but not with CD95 expression (rho between 0.01
and 0.12, e.g., Fig. 4f).
To avoid reducing the power of the statistical analysis, PD-L1
and CD95 biomarkers have been considered on a continuous
scale. First, the tumor response evaluated at 3 months was
categorized into 4 groups: progressive disease (PD, n= 127, 67%),
stable disease (SD, n= 31, 16%), partial response (PR, n= 18, 9%)
and complete response (CR, n= 14, 7%) (Supplementary Table 2).
The chosen binary outcome for the logistic regression model
was: PD (n= 127, 67%) vs. SD + PR + CR (n= 63, 33%).
Supplementary Table 3 shows the impact of clinical covariates
on tumor response and survival endpoints (PFS and OS). Even if
some of the presented clinical covariates were not signiﬁcant in
the univariate analysis, we kept them all in the ﬁnal model as they
are recognized as potential prognostic factors. Hence, ﬁnal
models were stratiﬁed on the centers and adjusted for LDH
(“low or high”, meaning below or above the normal value for each
clinical center), previous chemotherapy (“yes” or “no”), previous
immunotherapy (“yes” or “no”), previous protein kinase inhibitor
(“yes” or “no”), gender (“male” or “female”), age (continuous
scale) and tumor stage (III or IV). Regarding the clinical response
at 12 weeks, the expression of CD95 on CD4+ T cells was
observed to be prognostically associated in univariate analysis
(Fig. 5a, p= 0.023 [Cox modeling]), however, neither CD95 nor
PD-L1 on blood CD4+ and CD8+ T cells was observed to be
signiﬁcant in the multivariate analyses (Supplementary Table 4).
Of note, the association of PD-L1+/CD8+ on clinical response is
border line (Fig. 5b, p= 0.068 [Cox modeling] in multivariate
analyses).
Next, we analyzed the impact of those biomarkers on PFS (in
169 MMel including 143 events) and OS (in 189 MMel including
121 events). The 2-year PFS and OS were 17% (95% CI: 11–23%)
and 40% (95% CI: 32–47%), respectively (Supplementary Fig. 8).
Based on the univariate analysis, the highest prognostic clinical
covariates on PFS was history of protein kinase inhibition (PKI),
while LDH and previous chemotherapy/radiotherapy or PKI were
associated with the OS (Supplementary Table 3). PD-L1
expression on circulating CD4+ T cells and to a lesser extent on
CD8+ T cells were prognostic on PFS after CTLA-4 blockade
(Supplementary Table 5, p= 0.009 [Kaplan−Meier methods] for
PD-L1+CD4+ and p= 0.056 [Kaplan−Meier methods] for PD-L1
+CD8+ in multivariate analyses). Similarly, PD-L1+CD8+ T cells
was observed to be prognostic on OS (Fig. 6a, b, p= 0.011
[Kaplan−Meier methods] in multivariate analyses) outperforming
PD-L1+CD4+ T cells (p= 0.081 [Kaplan-Meier methods] in
multivariate analyses) (Supplementary Table 5). For both PFS and
OS, the higher is the expression of PD-L1, the higher the risk.
On the other hand, no signiﬁcant association was highlighted
between the CD95 expression (on both circulating CD4+ and
CD8+ T cells) and survival endpoints (Supplementary Table 5).
Even if no signiﬁcant association was observed, Fig. 6c illustrates
a protective tendency for patients with extremely low expression
level of CD95+ on CD8+ T cells. We also investigated a cutoff
value of 70% for the expression of CD95 on CD4+ T cells (Fig. 6d)
but did not ﬁnd association on OS in multivariate analysis. It
should be noted that the frequency of circulating PD-L1+CD8+
T cells impacted OS more than PFS with a hazard ratio± 95
conﬁdence interval for OS= 1.053 (1.012–1.096) and for PFS=
1.032 (0.999–1.065), in line with the fact that immune-related
parameters generally have a larger inﬂuence on OS than on
PFS23–25.
Altogether, our data indicate that PD-L1+ expression especially
on CD8+ T cells is associated with CTLA-4 blockade (mostly 3
mg/kg) for OS and borderline for RR and PFS in unresectable
stage III and IV MMel.
Predictive biomarkers of response to CTLA-4 + PD-1
co-blockade. The regimen of ipilimumab and nivolumab has
demonstrated impressive clinical beneﬁt in MMel (objective
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response rate (ORR) >60% with a PFS >11 months), but is also
associated with a high rate of immune related adverse events
(>50% grade 3–4 events)26. This supports further investigation
into biomarkers which may predict which patients may derive the
most beneﬁt to spare primarily resistant patients the toxicity of
the treatment. Given that the proportion of mLN that respond to
both anti-CTLA-4 and anti-PD-1 mAb separately was 11/37
(29%), among which 45% failed to respond to combined blockade
(Supplementary Table 1, Fig. 2), we hypothesized that predictive
biomarkers of response to this combination would have different
immunometrics than those identiﬁed for anti-CTLA-4 blockade.
Again, few immune parameters in blood and tumors were found
to be associated with functional responses to co-blockade
(Fig. 7a–d and Supplementary Fig. 9a, b). The two superior
immunometrics retained in the assay of 779 variables were the
expression levels of CD137/4-1BB on circulating CD4+ and CD8+
T lymphocytes (Fig. 7b, c). Detectable expression levels of CD137
on blood and tumor CD8+ T lymphocytes (and to a lesser extent
in CD4+ T cells) at diagnosis were correlated to response to
combined anti-PD-1/CTLA-4 mAbs (Fig. 7b, c, e, f). Based on
these ﬁndings obtained in blood and tumor, we hypothesized
that CD137 critically impacted sensitivity to CTLA-4/PD-1
co-blockade in MMel.
To assess the predictive value of CD137 expression on
circulating CD8+ T cells at baseline for clinical beneﬁt from the
combination of ipilimumab and nivolumab, we analyzed this
parameter in PBMCs obtained from a phase II adjuvant
trial assessing the efﬁcacy of nivolumab and ipilimumab
combination therapy in resected stage IIIc and IV MMel. The
median follow-up of this study was 13 months. The expression
levels of CD137 on circulating CD8+ T cells at baseline in
this cohort of patients was within the range of those
described above in patients with metastatic disease (Fig. 7g, h).
Interestingly, stage III MMel patients with resected high risk
disease who did not relapse after combination therapy expressed
much higher levels of CD137 on their circulating CD8+ T cells at
enrollment in the Phase II adjuvant trial, compared with
the levels in patients who had a relapse (p= 0.004 [Wilcoxon
rank-sum test]) (Fig. 7g).
Of note, low CD137 expression on CD8+ T cells did not predict
relapse in patients with high-risk resected melanoma treated with
nivolumab alone as anticipated from our correlative matrices
(Fig. 7h). To analyze which biomarker was best associated with
clinical outcome to PD-1 blockade, we returned to the ex vivo
mLN assay described above. The best immunometrics obtained
on circulating T cells and retained in the model of 779 variables
were (i) PD-1 expression levels on CD4+ T cells, (ii) the ratio
between CD8+ lymphocytes and CD127lowCD25high CD4+ Treg
cells, (iii) PD-L1 expression on CD4+ and CD8+ T cells as shown
for ipilimumab (Supplementary Fig. 10a). Indeed, higher
expression levels of PD-1 (>20%) in circulating CD4+ T cells at
diagnosis was associated with the likelihood to respond in the
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ex vivo mLN functional assays using anti-PD-1 mAb (but not
other mAbs; p< 0.02 [Wilcoxon rank-sum test], AUC= 0.75)
(Supplementary Fig. 10b). A CD8+ T cell/Treg ratio >5 also
tended to predict ex vivo reactivity of mLN to PD-1 blockade (but
not to another I-O axis; p< 0.06 [Wilcoxon rank-sum test], AUC
= 0.73) (Supplementary Fig. 10c). Similar to CTLA-4 blockade,
lower expression levels of PD-L1 on circulating CD4+ and CD8+
T cells were associated with ex vivo reactivity of PD-1 blockade
(Supplementary Fig. 10d).
Altogether, this study demonstrates that the ex vivo mLN
assay, as well as the preselected biomarkers of response or
resistance to mAbs may identify patients likely to respond to, or
fail to beneﬁt from the proposed therapy.
Discussion
We describe new predictive biomarkers of response to CTLA-4
blockade and to effective but potentially toxic combination
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therapy composed of anti-CTLA-4 + anti-PD-1 mAbs. These
results are based on a functional method called “the ex vivo mLN
assay”, capable of assessing the reactivity of metastatic
lymph node inﬁltrating immune effectors (T and NK cells) during
stimulation with various ICB or agonistic mAbs and their
combinations. This was coupled with a paired blood and tumor
immune proﬁling of mLN in stage III MMel with the intention of
correlating immune ﬁngerprints with clinical parameters27, 28.
We elucidated the relevance of PD-L1 expression on circulating
T cells for the prediction of resistance to ipilimumab, alone or
combination with IL-2 or GM-CSF. Moreover, our study shows
that detectable levels of CD137 on circulating CD8+ T cells after
LN or metastatic resection in stage IIIc and IV melanoma
tends to predict longer PFS for the anti-CTLA-4 + anti-PD-1
co-blockade.
The ex vivo mLN assay was feasible for almost all mLN
specimens containing at least 107 cells (37/46 were successfully
performed and contained enough cells for the “ex vivo mLN
assay”). Of note, this method could be downscaled to the size of a
biopsy if only 1 or 2 mAbs had to be tested. The method is also
reliable in that the two negative controls used (18–24 h or a 4–5
day incubation in the absence of stimulus or in the presence of Ig
control mAb) allow the basal assessment of T cell functions to be
determined19 with low non-speciﬁc backgrounds. The high
dose rIL-2 and rIFNα2a positive controls almost invariably
triggered effector (and Treg) proliferation and CXCL10
release, respectively, in all patients. We show that this method can
analyze important dynamic T and NK cell parameters relevant to
effector functions against cancer, such as proliferation and release
of Th1 cytokines, as well as proportions of Tregs in the co-culture
system. Cytokine and chemokine release could be considered as
surrogate markers for effector cell trafﬁcking or homing to
inﬂammatory sites.
It should be noted that the biomarkers that we chose to validate
and that were initially characterized in the discovery cohort were
chosen without adhering to the usual practice of correcting for
multiple comparisons. Rather, we preferred to include candidate
biomarkers based on raw (univariate) p-values of <0.05 that
reﬂected results that could be robustly quantiﬁed and that
appeared biologically relevant with fold changes between positive
and negative controls of >1.5 for a given axis. It is only by
testing additional cohorts of patients who received ipilimumab
in vivo that these candidate biomarkers acquired a potential
signiﬁcance.
The ﬁndings from our study indicate that the mLN reactivity to
immunomodulators is speciﬁc for each patient since (i) a precise
and speciﬁc pattern of immune activation for each mAb or
their various combinations across patients was not possible, in
contrast to generalizable responses to rIL-2 or rIFNα2a; (ii) each
individual patient exhibited a speciﬁc pattern of response to the
panel of stimulatory agents. Interestingly, our long-term expertise
with this ex vivo tumor restimulation assay underscores
the relevance of the tumor microenvironment in dictating the
functional outcome. Indeed, GIST responded best to anti-IL-10
or anti-TRAIL mAbs or rIFNα2a, rather than to anti-PD-1 or
anti-CTLA-4 mAbs29.
Our study also uncovers, for the ﬁrst time, two biomarkers of
resistance or response to I-O regimens: ipilimumab alone or
combined with PD-1 blockade. Herein, we found that the most
prominent markers predicting response to such regimens were
not the obvious candidates. PD-L1 (and not CTLA-4) on T cells
was found crucial for the prediction of resistance to anti-CTLA-4
mAb, whereas CD137 expression on circulating CD8+ T cells
appears a promising predictor of long term (>13 months)
relapse-free survival mediated by the combination of anti-PD-1
and anti-CTLA-4 mAbs in the adjuvant setting. This should be
investigated further in the metastatic setting and validated in
additional adjuvant patients.
Most previous biomarker studies with PD-1/PD-L1 antibodies
have focused on the prognostic signiﬁcance of PD-L1 (and/or
PD-L2) expression on tumor cells or myeloid cells of the TME.
Expression of both PD-L1 and PD-L2 signiﬁcantly correlated
with increasing densities of immune cells in the tumor specimens
and with immunotype. Positive PD-L2 expression alone or
combination with PD-L1 expression, was associated with
improved overall survival30. High PD-L1 expression on
melanoma were found predominantly in regions of abundant
inﬂammation or TIL inﬁltrates, even in sanctuaries like brain
metastases31, but it failed to predict responses to ICB in MMel.
To our knowledge, this is the ﬁrst comprehensive analysis of
the predictive role of PD-L1 expression on peripheral blood
T cells in melanoma. This expression might reﬂect the chronic
exposure to type 1−type 2 IFNs in the TME in recirculating
TILs20, as already reported in tumor cells themselves32.
In contrast, we could not identify a signiﬁcant association
of the CD95/CD4 biomarker neither with OS nor PFS in
multivariate analyses in these cohorts of MMel. However, given
its biological relevance33–43, higher levels (>70%) detected in
MMel (compared with HV), and co-expression of a variety of
inhibitory receptors on CD95+CD4+ T cells (such as PD-1, and
HLA-DR, Supplementary Fig. 7), it might still be interesting
to consider this biomarker in prospective studies using cutoff
values >70%.
The combination of ICBs ipilimumab and nivolumab has been
FDA-approved for ﬁrst-line treatment of unresectable MMel.
This approval followed the results of CheckMate 06726–06944,
trials where the combination of ipilimumab and nivolumab
outperformed each single agent alone in terms of response rates
and PFS. Additionally, recently published data in non-small
cell lung cancer patients have shown promising results for the
combination of anti-PD-L1 and anti-CTLA-4 mAbs in a phase 1b
clinical trial45. Hence, such combinations may be integrated into
the ever-changing melanoma treatment algorithm, and will most
likely be extended to other malignancies sensitive to PD-1
blockade. However, drug-related adverse events of grade 3 or 4
have been reported in 54% of patients receiving ipilimumab/
nivolumab combination therapy, as compared with 24%
of patients receiving ipilimumab monotherapy46, 47. Such
immune-related adverse events are generally reversible with
immunosuppressive medications. Given the efﬁcacy and relative
safety of nivolumab alone, ﬁnding a predictor of response to such
potentially toxic combinations is an urgent unmet clinical need.
Here, we propose a biomarker of response to ipilimumab +
nivolumab: the presence of detectable levels of CD137 on blood
CD8+ T cells, which appears to be signiﬁcantly associated with a
lack of relapse in resected high-risk, treatment-naive stage III
MMel. This novel biomarker is based on the following data:
(i) circulating T-lymphocytes expressing CD137 could be found
in the blood of patients with no evidence of disease with a median
follow-up of 13 months who received the combination in
an adjuvant setting (and not in those where nivolumab was
administered alone); (ii) the ﬁnding from the ex vivo mLN assay
that CD137 is upregulated in CD4+ and CD8+ TILs in
lesions found to be “responding” to ex vivo stimulation with the
combination of anti-PD-1 + anti-CTLA-4 mAbs (and not to
anti-PD-1 mAb or to other combinatorial regimens). It is
therefore conceivable that this combinatorial stimulation leads to
the engagement of the CD137/CD137L co-stimulatory pathway,
required for T cell ﬁtness and recirculation in the blood of
responders20. However, this pathway did not appear responsible
for tumor rejection mediated by the combination regimen in
mouse models, although the addition of an agonistic CD137 mAb
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to the combination therapy further delayed tumor outgrowth in a
therapeutic MCA-induced sarcoma model (MJS, unpublished
data). This data conﬁrm a previous study performed in
mouse ovarian carcinomas, where agonistic anti-CD137 mAb
augmented the impact of anti-PD-1 + anti-CTLA-4 mAb
therapy48.
These novel predictive immunometrics add to the long list of
putative biomarkers potentially relevant for ICB therapies. Our
previous experience suggested that high LDH levels, CXCL11 and
sCD25 concentrations in the serum negatively predict time to
progression in ipilimumab-treated stage IV MMel49–52, whereas
CLA (Cutaneous Lymphocyte Antigen) expressing CD8+ TEM
represent a pharmacodynamic signature of sensitivity to CTLA-4
blockade20. HLA subtype53, genetic polymorphisms54, and
absolute lymphocyte counts55 have not been validated as
immunotherapy biomarkers. A number of alternative parameters
such as high baseline levels of Foxp3 and IDO expression54,
increased TILs and Th1 cells at baseline56, MDSC
numbers50, 57, 58, T cell ICOS expression as pharmacodynamic
markers59, and (more recently) high mutational load and
neoantigen landscape60, 61, have yet to be prospectively studied as
biomarkers for the efﬁcacy of immunotherapy for melanoma.
A number of biomarkers of response to anti-PD-1/PD-L1
mAbs have been considered promising for future prospective
validation. For example, selective CD8+ T cell tumor inﬁltration
(often correlated with PD-L1 expression) and their distribution
at tumor invasive margins preceding PD-1 blockade appear
to predict ORR in stage IV melanoma62–64. Similarly, the
immunohistochemical determination of PD-L1 expression
(although lacking a standardized methodology and subject to
variable expression depending on timing and biopsy sites)
may guide the choice between PD-1 blockade vs. CTLA-4 + PD-1
co-blockade63–65. A high mutational load is also associated with
clinical responses to the PD-1 regimen66. Moreover, high relative
eosinophil count, and lymphocyte count, low LDH and absence
of metastasis other than soft-tissue or lung at baseline
are associated with a favorable OS in patients treated with
pembrolizumab67. Whether the proposed blood biomarkers
identiﬁed in our study (PD-1 expression on CD4+ T cells, PD-L1
expression on CD4+ and CD8+ T cells, or the CD8+ T cell/Treg
ratio in blood) would also be useful to predict the efﬁcacy of PD-1
blockade remains to be elucidated in large retrospective and then
prospective cohorts. Our ﬁndings suggest that prospective ICB
adjuvant trials in stage III−IV MMel could be personalized based
on (i) ex vivo mLN assays or (ii) blood biomarkers capable of
predicting such response. Obviously, further clinical trials are
necessary to validate this prediction.
Methods
Experimental design. In a cohort of stage III MMel patients, we previously
reported the immune parameters that were signiﬁcantly associated with outcome19.
We established an ex vivo assay based on the reactivity of immune cells from 37
dissociated metastatic lymph nodes to mAbs and cytokines. We arbitrarily
deﬁned “responding” lesions, those exhibiting a more than 1.5-fold change over
two different controls (medium and IgG) in two independent biological readouts
(out of 40 readouts measured, 35 were retained with a threshold of 95% of detected
values). This stratiﬁcation into responders (R) vs. non-responders (NR) enabled us
to deﬁne in a retrospective manner which parameters expressed by peripheral or
inﬁltrating T cells were essential for this response. Furthermore, we demonstrated
the validity of the method by analyzing the predictive value of some parameters on
retrospective clinical cohorts including 190 unresectable stage III−IV MMel
patients.
Study approval. Institutional review board approvals were granted by the
University of Tübingen, the University of California, the University Hospital of
Copenhagen, the University Hospital of Zürich, the University Hospital of Siena,
the Sharett Institute of Oncology, the Aarhus University Hospital, the Centre
Hospitalier de Nantes, and the Providence Cancer Center (for the ipilimumab-
treated cohorts), the Laura & Isaac Perlmutter Cancer Center (for ipilimumab +
nivolumab and nivolumab) and Gustave Roussy/Kremlin Bicêtre and Centre
Hospitalier Lyon-Sud for the prospective cohort and retrospective cohorts
(Supplementary Fig. 7d) which were previously described68, 69. The human study
protocols were in accordance with the Declaration of Helsinki principles, and all
patients provided informed consent before enrollment in the study.
Prospective cohort of 37 patients. This cohort and its clinical parameters have
been previously described19.
Retrospective cohorts of 190 ipilimumab-treated patients. Patients enrolled in
this study were from several centers: the University of Tübingen, University of
Siena, University of California, University Hospital of Copenhagen, University
Hospital of Zürich, Sharett Institute of Oncology, Aarhus University Hospital,
Centre Hospitalier de Nantes, and the Providence Cancer Center. In all cohorts,
blood samples were collected before injections of ipilimumab from patients
participating in evaluations of ipilimumab as adjuvant therapy. Markers were
assessed on PBMCs with the exception of the Sharett Institute of Oncology cohort
(assessed on whole blood) after thawing. Patients’ characteristics can be found in
Supplementary Table 2.
Retrospective study on the adjuvant Phase II trial testing nivolumab + ipili-
mumab vs. nivolumab-treated patients. Information regarding this clinical trial
can be found in reference70.
PBMC and TILs preparations. Peripheral blood samples from patients or HV
were carefully layered on top of a Ficoll-Hypaque density gradient media (PAA
Laboratories). The ring of PBMC was collected and washed twice in PBS, resus-
pended in PBS, counted and stained for ﬂow cytometric analyses or resuspended in
CryoMaxx medium (PAA Laboratories) for storage in liquid nitrogen. Resected
mLN specimens from MMel patients were placed in isotonic solution at least for 1
h. Next, tissue was cut and placed in dissociation medium, which consisted of
RPMI1640, 1% penicillin/streptomycin (PEST, GIBCO Invitrogen), Collagenase IV
(50 IU/ml), hyaluronidase (280 IU/ml), and DNAse I (30 IU/ml) (all from Sigma-
Aldrich), and run on a gentle MACS Dissociator (Miltenyi Biotec) during 1 h. Cell
samples were diluted in PBS, passed through a cell strainer and centrifuged for 5
min at 1500 r.p.m. Cells were ﬁnally resuspended in PBS, counted, stained for ﬂow
cytometric analyses or resuspended in CryoMaxx medium (PAA Laboratories) for
storage in liquid nitrogen. All mLN included in the study were histologically
conﬁrmed to be invaded and patients enrolled in this prospective cohort were free
of prior Abs-based immunotherapies.
Ex vivo mLN assays. Dissociated cells from mLN were incubated in two 48-well
plates at 0.3 × 106/ml in complete medium (RPMI 1640 supplemented with 10%
human AB serum [Institut de Biotechnologie Jacques Boy], 1% Penicillin/Strep-
tomycin, 1% L-glutamine and 1% of sodium pyruvate [all from Gibco-Invitrogen])
and with isotype control, agonistic (CD137/CD137L) or antagonistic (PD-1/PD-L1,
CTLA-4, Tim-3) mAbs or cytokines (IFNα2a [Roferon, ROF], IL-2) or their
combinations (PD-1 + ROF, CTLA-4 + ROF, PD-1 + Tim-3, PD-1 + CTLA-4) as
described in the Supplementary Fig. 1 and Supplementary Tables 1 and 7. After
18–24 h of incubation with or without drugs, cells were stimulated with PMA (5
ng/ml) (Sigma), ionomycin (125 ng/ml) (Sigma), and BD Golgi Stop (4 µl per 6 ml)
(BD Biosciences) for 3−5 h. Cells were then collected, membrane stained to
discriminate between different lymphocyte subsets (Supplementary Table 8),
permeabilized with BD Cytoﬁx/CytopermTM kit (BD Biosciences). Intracellular
staining was then performed using anti-IFNγ PE (BD Biosciences, clone B27) and
anti-TNFα AF647 (BioLegend, clone Mab11) mAbs. For the second plate, after 4
−5 days of culture with or without drugs, cells were collected and membrane
stained, permeabilized with Foxp3/Transcription factor Fixation/Permeabilization
kit (eBiosciences) and intranuclearly stained with anti-Ki67 PE (BD Biosciences,
clone B56) and anti-Foxp3 APC (eBiosciences, clone PCH101) mAbs following
the manufacturer’s recommendations. We arbitrarily deﬁned “biological
responses”, as those exhibiting a >1.5-fold increase over the values obtained with
two negative controls (medium and Ig control mAb) in at least two independent
biological readouts, except for CD4+FoxP3+ Treg for which a response was deﬁned
as a >1.5-fold decrease compared with the baseline levels in responders compared
to non-responders.
Flow cytometric analyses. For membrane labeling, PBMC and TILs were stained
with ﬂuorochrome-coupled mAbs (detailed in Supplementary Table 8), incubated
for 20 min at 4°C and washed. Cell samples were acquired on a Cyan ADP 9-color
(Beckman Coulter), BD FACS Canto II ﬂow-cytometers or on an 18-color BD
LSRII (BD Biosciences) with single-stained antibody-capturing beads used for
compensation (Compbeads, BD Biosciences or UltraComp eBeads, eBiosciences).
Data were analyzed with FlowJo software v7.6.5 or v10 (Tree Star, Ashland, OR,
USA).
Cytokine and chemokine measurements. Supernatants from cultured cells were
monitored using the human Th1/Th2/Th9/Th17/Th22 13-plex RTU FlowCytomix
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Kit (eBiosciences), and human chemokine 6-plex kit FlowCytomix (eBiosciences)
according to the manufacturer’s instructions and acquired on a Cyan ADP 9-color
ﬂow cytometer (Beckman Coulter). Analyses were performed by FlowCytomix Pro
3.0 Software (eBiosciences). Some measurements were performed by ELISA
with IFNγ (BioLegend), IL-9 (BioLegend), TNFα (BD Biosciences), CCL2 (BD
Biosciences), CCL3 (R&D Systems), CCL4 (R&D Systems), CCL5 (R&D Systems),
and CXCL10 (BD Biosciences) kits in accordance with the manufacturer’s
recommendations.
Statistics. Data analyses were performed with the R software (http://www.R-
project.org/). Graphical representations were performed either with R or Prism 5
(GraphPad, San Diego, CA, USA). For the “ex vivo metastatic lymph node (mLN)
assay” 124 (blood) and 128 (tumor) parameters were analyzed and reported. The
effectiveness of these biomarkers on resistance to CTLA-4 blockade was reported
and graphed using the log transformed ratio between responders and non-
responders or the area under the ROC curve (AUC statistic) on the x-axis and the
Wilcoxon rank-sum test p-values on the y-axis. Distribution of biomarkers were
also plotted through box and whiskers plots. Regarding the retrospective cohort
evaluation, logistic regressions (univariate and multivariate) have been used to
assess the association of covariates on binary endpoint (i.e., clinical response).
Two survival endpoints were also evaluated: (i) overall survival (OS) was deﬁned as
the time from the date of sampling to death or the last follow-up, whichever
occurred ﬁrst and (ii) PFS was deﬁned as the time from the date of sampling to
death, disease progression or the last follow-up, whichever occurred ﬁrst. For both
survival endpoints (OS and PFS), survival curves were estimated using the Kaplan
−Meier method by dichotomizing biomarkers through their median value or a
chosen cutoff based on HV. The decision between median vs. a cutoff, is based on
the fact that the PD-L1+CD8+ cells in most healthy volunteers were undetectable
(with values close to 0), meaning that most of the patients would have been
classiﬁed as supranormal. Therefore, we chose to calculate the median values
for patients with respect to this parameter. In sharp contrast, the values of
CD95+CD4+ cells in healthy volunteers were sizeable, allowing to estimate a
threshold above which the patients could be considered supranormal. Cox models
have been used to perform univariate and multivariate analysis. Graphical visua-
lization of the effect of continuous biomarkers has been performed by modeling
them through splines with 2 degrees of freedom. All the logistic and Cox models
evaluated the biomarkers based on a continuous scale, were stratiﬁed on the
centers, and adjusted for LDH, gender, age, tumor stage, CT, IT, and PKI as
indicated in Supplementary Tables 3−6. In all cases, conﬁdence intervals were
reported at a nominal level of 95%.
Data availability. An MTA was signed between Gustave Roussy and Laura and
Isaac Perlmutter Cancer Center.
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